The clinical picture of early-stage Parkinson’s disease. errors in the diagnosis of different forms
https://doi.org/10.14412/2074-2711-2013-2415
Abstract
About the Authors
E N GubanovaDepartment of Neurology
Natalia Vladimirovna Fedorova
Department of Neurology
References
1. <div><p>Lees A.J. Drugs for Parkinson's disease J Neurol Neurosurg 2002;73:607-10.</p><p>Marsden C.D. Parkinson's disease J Neurol Neurosurg Psychiatry 1994;57:672-81.</p><p>Karlsen K.H., Larsen J.P., Tandberg E. et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;6:431-5.</p><p>Левин О.С., Лавров А.Ю., Шиндряева Н.Н. и др. Эпидемиология болезни Паркинсона. Болезни движений: медицинские и социальные аспекты. М., 2010;24.</p><p>Hoehn M.M., Yahr H.D. Parkinsonism: Onset, Progression and mortality. Neurology 1967;17:427-42.</p><p>Stern M.B., Olanow C.W., Sethi K. The Scientific and Clinical Basis for the Treatment of Parkinson's Disease. Neurology 2009;72(21, Suppl 4):1-136.</p><p>Doty R.L. The olfactory system and its disorders. Semin Neurol 2009b;29(1):74-81.</p><p>Poewe W. When PD patient start to hallucinate. Pract Neurol 2008;8:238-41.</p><p>Olson L.G., Ambrobetti A., Gyulay S.G. Prediction of sleep-disordered breathing by unattended overnight oximetry. J Sleep Res 1999;8:51-5.</p><p>Ravina B., Marder K., Fernandez H.H. et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Mov Disord 2007;8:1061-68.</p><p>Nilsson A., Hanssen E., Ericsson P. Hetеroheneity among astrocytes, evaluated biochemical parameters. Adv Biosci 1986;61:235-41.</p><p>Ishihara L.S., Cheesbrough A., Brayne C. et al. Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Phychiatry 2008;89:1404-09.</p><p>Braak H., Del Tredici K., Bratzke H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249(Suppl 3):1-5.</p><p>Pieri V., Diederich N.J., Goetz C.G. Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenic comparison. Fortschr Neurol Psychiat 2000;68:129-36.</p><p>Hawkes C.H. The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? Mov Disord 2008;23:1799-807.</p><p>Gonera E.G., van't Hof M., Berger H.J.C. et al. Symptoms and duration of the premotor phase in Parkinson's disease. Mov Disord 1997;12:871-76.</p><p>Gibb W.R., Lees A.J. The significance of the Levy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27-44.</p><p>Hughes A.J., Ben-Shlomo Y., Daniel S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-46.</p><p>Gibb W.R.G., Less A.J. Relevarae Levy body pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychyatry 1998;51:745—52.</p><p>Федотова Е.Ю., Чечеткин А.О., Шадрина М.И. и др. Транскраниальная сонография при болезни Паркинсона. Журн неврол и психиатр 2011;111:49—55.</p><p>Berg D., Roggendorf W., Schroder U. et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibilit to nigrostriatal injury. Arch Neurol 2002;59:999—1050.</p><p>Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;8:429—33.</p><p>Brooks D.J. Detection of preclinical Parkinson's disease with PET. Neurology 1991;41:24—27.</p><p>Morrish P.K., Sawle G.V., Brooks D.J. An 18F-dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:223—591.</p><p>Brooks D.J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000;247(Suppl 2):11—8.</p><p>Brooks D.J. The early diagnosis of Parkinson's disease. In: Beyond the decade of the brain. Neuroprotection in Parkinson's disease. C.W. Olanow, P. Jenner (eds). Kent: Wells Medical Limited, 1998;3:37—41.</p><p>Booij J., Tissingh G., Winogrodzka A., van Royen E.A. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171—82.</p><p>Seibyl J.P., Marek K.L., Quinlan D. et al. Decreased single-photon emission computed tomographic [123I]-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589—98.</p><p>Левин О.С., Федорова Н.В., Шток В.Н. Дифференциальная диагностика паркинсонизма. Журн неврол и психиатр 2003;3:54—60.</p><p>Stacy M., Jankovic J. Differential diagnosis of Parkinson's disease and parkinsonism-plus syndromes. Neurol Clin 1992;10:341—59.</p><p>Левин О.С., Федорова Н.В. Болезнь Паркинсона. М.: МЕДпресс-информ 2012;8:77—84.</p><p>Левин О.С. Сосудистый паркинсонизм. Неврол журн 1997;4:42—51.</p><p>Jellinger K.A. Critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2010;67:550.</p><p>Pfeiffer R.F., Bodis-Wollner I. Parkinson's disease and nonmotor dysfunction. Humana Press 2005;3:308.</p><p>Goetz C.G. Tanner C.M., Levy M. et al. Pain in Parkinson's disease. Mov Disord 1986;1:45—9.</p><p>Brooks D.J., Doder M. Depression in Parkinson's disease. Curr Opin Neurol 2001;14:456—70.</p><p>Cummings J.L. Depression in Parkinson's disease. Am J Psychiatry 1992;149:443—54.</p><p>Hubble J.P., Cao T., Hassanein R.E. et al. Factors for Parkinson's disease. Neurology 1993;43:1693—97.</p><p>Burn D.J. Depression in Parkinson's disease. Eur J Neurol 2002;9(Suppl 3):44—54.</p></div><br />
Review
For citations:
Gubanova E.N., Fedorova N.V. The clinical picture of early-stage Parkinson’s disease. errors in the diagnosis of different forms. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):58-63. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2415